{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.43","upperLimit":"23.59","value":"14.9"},{"groupId":"OG001","lowerLimit":"12.22","upperLimit":"20.17","value":"14.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"598"},{"groupId":"OG001","value":"602"}],"units":"Participants"}],"description":"The ECOG PS was used to evaluate participant's DP and the effect of the disease on the participant's activities of daily living. It ranges on the scale from 0-5 (0= normal activity; 1= symptoms but ambulatory; 2= in bed for \\< 50 % of the time; 3= in bed for \\> 50% of the time; 4= 100% bedridden; 5= dead). Time to definitive deterioration in ECOG PS score from baseline was defined as a change from 0, 1 to ≥2, or from 2 to ≥3. Analysis was performed by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG000","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG001","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on ITT population.","reportingStatus":"POSTED","timeFrame":"From baseline until death or study cut-off date (maximum duration: 48 months)","title":"Time to Definitive Deterioration of ECOG PS Score From Baseline","type":"SECONDARY","unitOfMeasure":"months"}